Background/aim: Fractionated conformal radiotherapy (FCRT) is now used to treat vision-threatening optic nerve sheath meningioma (ONSM), but long-term efficacy and safety data are lacking; the purpose of this study was to assess these key data.
Methods: This is a retrospective chart review with prospective follow-up of adult patients treated with FCRT for primary ONSM at four academic medical centres between 1995 and 2007 with ≥10 years of follow-up after treatment.
Results: 16 patients were identified with a mean post-treatment follow-up of 14.6 years (range: 10.5-20.7 years). The mean age at symptom onset was 47.6 years (range: 36-60 years). FCRT was performed at a mean of 2.3 years after symptom onset (range: 0.2-14.0 years). At last follow-up, visual acuity had improved or stabilised in 14 of the 16 (88%) patients, and 11 (69%) had retained or achieved ≥20/40. The mean deviation on automated perimetry remained stable (-14.5 dB pretreatment vs -12.2 dB at last follow-up; p=0.68, n=10). Two (11%) patients had persistent pain, proptosis or diplopia, compared with six (38%) pretreatment (p=0.11). Two (13%) patients developed radiation retinopathy more than 6 months after completion of therapy, one (50%) of whom had worse visual acuity compared with pretreatment. No patient developed tumour involvement or radiation damage in the fellow eye.
Conclusion: FCRT stabilises or improves visual function in patients with primary ONSM and is associated with a low risk of significant ocular sequelae. This treatment should be considered instead of surgery in patients with primary ONSM who require intervention due to loss of visual sensory and/or ocular motor function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjophthalmol-2018-313135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of safety and efficacy of proton radiotherapy for optic nerve sheath meningioma.
Neurooncol Adv
September 2024
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Article Synopsis
- Primary optic nerve sheath meningiomas (ONSMs) are benign tumors that can cause gradual vision loss, and radiation therapy, particularly proton therapy, is key for treatment as it may improve visual function while minimizing side effects.* -
- In a study of 32 patients treated with proton beam radiotherapy, results showed a 100% local control rate after 5 years and 84.4% of patients experienced improved or stable vision, despite a 9.4% occurrence of radiation-induced optic neuropathy (RION).* -
- The findings support proton beam therapy as a safe and effective option for ONSM treatment, though further research is needed to compare its effectiveness against traditional photon radiotherapy.*
Role of hypofractionated stereotactic radiotherapy for primary optic nerve sheath meningioma.
Neurooncol Pract
April 2024
Department of Radiation Oncology, Hacettepe University School of Medicine, Ankara, Turkey.
Article Synopsis
- This study focuses on the effectiveness of hypofractionated stereotactic radiotherapy (HF-SRT) in treating rare optic nerve sheath meningiomas (ONSM), which can lead to vision problems.
- A total of 36 patients were treated, and results showed that 64% of tumors regressed and 89% achieved local control, with the majority of patients maintaining or improving their visual acuity over an average follow-up period of 106 months.
- The findings suggest that HF-SRT is a safe and effective treatment, with an emphasis on starting therapy before significant vision loss occurs, particularly noting that female patients had better visual outcomes.
Optic Nerve Sheath Meningiomas: A National Surveillance, Epidemiology, and End Results (SEER) Database Analysis.
J Neuroophthalmol
September 2024
Dean McGee Eye Institute (ZSH, KMR), Oklahoma City, Oklahoma; University of Medicine and Health Sciences (ZSH), Basseterre, Saint Kitts and Nevis; Department of Ophthalmology (AL), Baylor College of Medicine, Houston, Texas; Center for Space Medicine (AGL), Baylor College of Medicine, Houston, Texas; The Houston Methodist Research Institute (AGL), Houston Methodist Hospital, Houston, Texas; Departments of Ophthalmology, Neurology, and Neurosurgery (AGL), Weill Cornell Medicine, New York, New York; Department of Ophthalmology (AGL), University of Texas Medical Branch, Galveston, Texas; University of Texas MD Anderson Cancer Center (AGL), Houston, Texas; Texas A&M College of Medicine (AGL), Bryan, Texas; and Department of Ophthalmology (AGL), The University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Background: Optic nerve sheath meningioma (ONSM) is a rare optic nerve cancer with considerable morbidity. This national analysis validates previously known ONSM concepts while providing insight into novel risk factors.
Methods: The Surveillance, Epidemiology, and End Results (SEER) Program was queried from 2000 to 2019 for all histologic subtypes of meningioma primary to the optic nerve.
Does Adjuvant Gamma Knife Stereotactic Radiosurgery Have a Role in Treating Optic Nerve Sheath Meningiomas?
J Neuroophthalmol
June 2024
Departments of Neurological Surgery (ZW, HD, AN, LDL) and Neurology (SS), University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and University of Pittsburgh School of Medicine (ZW, ST), Pittsburgh, Pennsylvania.
Background: Meningiomas arising from or adjacent to the optic nerve sheath meningioma (ONSM) are management challenges because of their risk of visual loss. Stereotactic radiosurgery (SRS) is a minimally invasive modality that can be added as adjuvant treatment for patients whose tumor has progressed or recurred after initial resection.
Methods: The authors retrospectively reviewed 2,030 meningioma patients who underwent SRS between 1987 and 2022.
The treatment efficacy of radiotherapy for optic nerve sheath meningioma.
Eye (Lond)
January 2024
Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Objectives: Optic nerve sheath meningioma (ONSM) is a rare benign tumour that accounts for approximately 2% of all orbital tumours. Radiotherapy has gradually become an important treatment for ONSM because of its good effect in preserving or improving vision. We aimed to explore the effect of radiotherapy on tumour control and vision preservation/improvement in patients with ONSM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!